48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

NCT00654602 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1500

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidaemia

Interventions

DRUG: Rosuvastatin
BEHAVIORAL: Maintenance of specific diet

Sponsor

AstraZeneca